Last veterinary health company Zomedica Corp (NYSEAMERICAN:ZOM) had been in deep focus among many investors after it had launched its veterinary diagnostic platform. However, 2022 has been a fairly forgettable year for the company’s investors as the stock has suffered from a steady selloff and clocked decline of 18% so far.
Trading Data
On Wednesday, ZOM stock moved up 2% to $0.2978 with 15.08 million share, compared to its average volume of 13.69 million shares. The stock moved within a range of $0.2900 – 0.3039 after opening trade at $0.29.
Zomedica Announces Management Team Additions
Considering the prolonged slump in the Zomedica stock, it could be a good time for investors to try and figure out if the stock is going to be in freefall or if there is going to be a rebound. As it happens, the company was actually in the news yesterday after it made an announcement with regards to new additions to its management team.
One of the new addition that was made by the company was that of Tony Blair in the capacity of Executive Vice President. He is a highly experienced executive and has worked in the manufacturing sector for more than three and a half decades. The other appointment was that of Kristin Domanski as the Vice President of Human Resources. Last but certainly not the least, it was Evan Saint-Peter who was drafted in as the Vice President of Technology Innovation at Zomedica.
Key Quote
“I’m excited to join the team at Zomedica and I’m optimistic about the future of the company,” said Tony Blair. “My goals are to develop and create the manufacturing and distribution capacity to support the projected growth of our company. I look forward to achieving these goals alongside the talented team members at Zomedica and PulseVet.”
Technical Data
ZOM stock is trading below the 20-Day and 50-Day Moving averages of $0.31 and $0.33 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.57.
